Research ArticleNEUROPHARMACOLOGY
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Béla Kiss, Attila Horváth, Zsolt Némethy, Éva Schmidt, István Laszlovszky, Gyula Bugovics, Károly Fazekas, Katalin Hornok, Szabolcs Orosz, István Gyertyán, Éva Ágai-Csongor, György Domány, Károly Tihanyi, Nika Adham and Zsolt Szombathelyi
Journal of Pharmacology and Experimental Therapeutics April 2010, 333 (1) 328-340; DOI: https://doi.org/10.1124/jpet.109.160432
Béla Kiss
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Attila Horváth
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Zsolt Némethy
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Éva Schmidt
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
István Laszlovszky
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Gyula Bugovics
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Károly Fazekas
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Katalin Hornok
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Szabolcs Orosz
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
István Gyertyán
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Éva Ágai-Csongor
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
György Domány
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Károly Tihanyi
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Nika Adham
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
Zsolt Szombathelyi
Research and Development, Gedeon Richter Plc., Budapest, Hungary (B.K., A.H., Z.N., E.S., I.L., G.B., K.F., K.H., S.O., I.G., E.A.-C., G.D., K.T., Z.S.); and Forest Research Institute, Division of Forest Laboratories Inc., Jersey City, New Jersey (N.A.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleNEUROPHARMACOLOGY
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Béla Kiss, Attila Horváth, Zsolt Némethy, Éva Schmidt, István Laszlovszky, Gyula Bugovics, Károly Fazekas, Katalin Hornok, Szabolcs Orosz, István Gyertyán, Éva Ágai-Csongor, György Domány, Károly Tihanyi, Nika Adham and Zsolt Szombathelyi
Journal of Pharmacology and Experimental Therapeutics April 1, 2010, 333 (1) 328-340; DOI: https://doi.org/10.1124/jpet.109.160432
Research ArticleNEUROPHARMACOLOGY
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Béla Kiss, Attila Horváth, Zsolt Némethy, Éva Schmidt, István Laszlovszky, Gyula Bugovics, Károly Fazekas, Katalin Hornok, Szabolcs Orosz, István Gyertyán, Éva Ágai-Csongor, György Domány, Károly Tihanyi, Nika Adham and Zsolt Szombathelyi
Journal of Pharmacology and Experimental Therapeutics April 1, 2010, 333 (1) 328-340; DOI: https://doi.org/10.1124/jpet.109.160432
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement